Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for AKRO

Stock NameAkero Therapeutics Inc
TickerAKRO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00973Y1082
LEI549300SI3KG74LBE2955

Show aggregate AKRO holdings

News associated with AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $81.57 Average Target Price from Analysts
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […] - 2025-09-05 02:52:56
Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at TD Cowen
TD Cowen assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $76.00 target price on the stock. AKRO has been the subject of several other research reports. Citigroup dropped their price target on shares of […] - 2025-08-07 02:54:52
Universal Beteiligungs und Servicegesellschaft mbH Invests $463,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,436 shares of the company’s stock, valued at approximately $463,000. A number of other […] - 2025-08-04 05:14:50
KLP Kapitalforvaltning AS Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
KLP Kapitalforvaltning AS decreased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 1,400 shares during the […] - 2025-07-31 05:14:49
Jennison Associates LLC Purchases Shares of 13,178 Akero Therapeutics, Inc. (NASDAQ:AKRO)
Jennison Associates LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,178 shares of the company’s stock, valued at approximately $533,000. Several other institutional investors and hedge funds have also […] - 2025-07-23 06:20:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Bank of New York Mellon Corp
Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,665 shares of the company’s stock after acquiring an additional 12,235 shares […] - 2025-07-22 08:19:03
Bank of New York Mellon Corp Acquires 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Bank of New York Mellon Corp raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,665 shares of the company’s stock after buying an additional 12,235 shares during the quarter. Bank […] - 2025-07-22 07:24:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,534,800.00 in Stock
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the sale, the chief executive officer directly owned 520,757 shares of the company’s […] - 2025-07-14 06:16:53
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of “Buy” by Brokerages
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […] - 2025-07-14 05:38:47
Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 14.5% during the first quarter, HoldingsChannel reports. The firm owned 2,664 shares of the company’s stock after buying an additional 338 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero Therapeutics were worth […] - 2025-07-07 04:41:41
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Target Price from Analysts
Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-06-24 03:11:00
Millennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Millennium Management LLC decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 77.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,736 shares of the company’s stock after selling 57,892 shares during the period. Millennium Management LLC’s holdings in Akero Therapeutics […] - 2025-06-10 05:18:54
Akero Therapeutics Sees Unusually High Options Volume (NASDAQ:AKRO)
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options. Insider Activity In other news, insider Timothy Rolph sold 12,500 shares of […] - 2025-06-10 02:00:51
Akero Therapeutics (NASDAQ:AKRO) Given New $64.00 Price Target at Bank of America
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price raised by Bank of America from $63.00 to $64.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Other research analysts also recently issued research reports about the company. Citigroup reduced their price target on Akero Therapeutics […] - 2025-05-28 02:44:51
ProShare Advisors LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
ProShare Advisors LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 32.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,398 shares of the company’s stock after acquiring an additional 5,477 shares during the period. ProShare Advisors LLC’s holdings in Akero Therapeutics were worth $623,000 as of […] - 2025-05-26 05:16:50
Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $78.00 by Analysts at Citigroup
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective decreased by Citigroup from $80.00 to $78.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also weighed in on AKRO. HC Wainwright raised their price objective on shares of Akero […] - 2025-05-14 04:58:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Average Price Target from Analysts
Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock […] - 2025-05-05 04:28:56
Sterling Capital Management LLC Boosts Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Sterling Capital Management LLC lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 764.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after purchasing an additional 1,582 shares during the period. Sterling Capital Management LLC’s holdings in Akero […] - 2025-04-24 05:56:54
Vanguard Group Inc. Has $103.06 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,704,411 shares of the company’s stock after purchasing an additional 27,830 shares during the period. Vanguard Group Inc. owned approximately […] - 2025-04-10 04:38:50
KLP Kapitalforvaltning AS Invests $306,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 11,000 shares of the company’s stock, valued at approximately $306,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of AKRO. Handelsbanken […] - 2025-04-07 05:06:49
Akero Therapeutics (NASDAQ:AKRO) and Rezolute (NASDAQ:RZLT) Head to Head Comparison
Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-26 04:10:42
Y Intercept Hong Kong Ltd Lowers Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,950 shares of the company’s stock after selling 7,966 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 at […] - 2025-03-05 07:07:16
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $75.00
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. AKRO has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Akero […] - 2025-03-04 04:50:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC
Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global […] - 2025-02-27 06:52:59
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last […] - 2025-02-19 05:06:50
Technology Stocks Upended by China’s DeepSeek
The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini S&P futures (ESH25 ) are down by -1.38%, and March E-mini Nasdaq... - 2025-01-28 13:04:47
Stocks Hit by AI Jitters
The S&P 500 Index ($SPX ) (SPY ) today is down -1.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.68%. March E-mini S&P futures (ESH25 ) are down sharply by -1.70%, and March E-mini... - 2025-01-28 02:53:37

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc AKRO holdings

DateNumber of AKRO Shares HeldBase Market Value of AKRO SharesLocal Market Value of AKRO SharesChange in AKRO Shares HeldChange in AKRO Base ValueCurrent Price per AKRO Share HeldPrevious Price per AKRO Share Held
2025-11-12 (Wednesday)6,335AKRO holding decreased by -20USD 343,991AKRO holding decreased by -768USD 343,991-20USD -768 USD 54.3001 USD 54.25
2025-11-11 (Tuesday)6,355USD 344,759AKRO holding increased by 699USD 344,7590USD 699 USD 54.25 USD 54.14
2025-11-10 (Monday)6,355USD 344,060AKRO holding increased by 636USD 344,0600USD 636 USD 54.14 USD 54.04
2025-11-07 (Friday)6,355USD 343,424AKRO holding increased by 826USD 343,4240USD 826 USD 54.04 USD 53.91
2025-11-06 (Thursday)6,355AKRO holding decreased by -20USD 342,598AKRO holding decreased by -1971USD 342,598-20USD -1,971 USD 53.91 USD 54.05
2025-11-05 (Wednesday)6,375AKRO holding decreased by -200USD 344,569AKRO holding decreased by -10678USD 344,569-200USD -10,678 USD 54.05 USD 54.03
2025-11-04 (Tuesday)6,575AKRO holding decreased by -40USD 355,247AKRO holding decreased by -2558USD 355,247-40USD -2,558 USD 54.03 USD 54.0899
2025-11-03 (Monday)6,615AKRO holding decreased by -40USD 357,805AKRO holding decreased by -2896USD 357,805-40USD -2,896 USD 54.0899 USD 54.2
2025-10-31 (Friday)6,655USD 360,701AKRO holding decreased by -399USD 360,7010USD -399 USD 54.2 USD 54.26
2025-10-30 (Thursday)6,655USD 361,100AKRO holding increased by 1730USD 361,1000USD 1,730 USD 54.26 USD 54
2025-10-29 (Wednesday)6,655USD 359,370USD 359,3700USD 0 USD 54 USD 54
2025-10-28 (Tuesday)6,655AKRO holding increased by 60USD 359,370AKRO holding increased by 4229USD 359,37060USD 4,229 USD 54 USD 53.85
2025-10-27 (Monday)6,595USD 355,141AKRO holding increased by 528USD 355,1410USD 528 USD 53.85 USD 53.77
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AKRO by Blackrock for IE00B3VWM098

Show aggregate share trades of AKRO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-2054.35054.215 54.228USD -1,085 44.88 Loss of -187 on sale
2025-11-06SELL-2054.10053.900 53.920USD -1,078 44.69 Loss of -185 on sale
2025-11-05SELL-20054.10054.000 54.010USD -10,802 44.64 Loss of -1,873 on sale
2025-11-04SELL-4054.10054.000 54.010USD -2,160 44.60 Loss of -377 on sale
2025-11-03SELL-4054.20054.000 54.020USD -2,161 44.55 Loss of -379 on sale
2025-10-28BUY6054.00054.050 54.045USD 3,243 44.34
2025-10-24SELL-2053.77053.890 53.878USD -1,078 44.24 Loss of -193 on sale
2025-10-15BUY12053.60053.900 53.870USD 6,464 43.86
2025-10-02BUY2046.41046.800 46.761USD 935 43.83
2025-09-30BUY4047.48048.030 47.975USD 1,919 43.80
2025-08-21SELL-2048.29048.460 48.443USD -969 43.72 Loss of -94 on sale
2025-07-31BUY6048.85049.360 49.309USD 2,959 43.66
2025-06-30SELL-4053.36056.510 56.195USD -2,248 42.65 Loss of -542 on sale
2025-06-25SELL-2055.04055.515 55.467USD -1,109 42.38 Loss of -262 on sale
2025-06-20SELL-4054.20055.000 54.920USD -2,197 42.13 Loss of -512 on sale
2025-05-23BUY2046.36048.500 48.286USD 966 40.52
2025-05-19SELL-2038.14039.250 39.139USD -783 40.34 Profit of 24 on sale
2025-05-15SELL-6039.96040.190 40.167USD -2,410 40.36 Profit of 11 on sale
2025-05-12SELL-2041.53042.180 42.115USD -842 40.37 Loss of -35 on sale
2025-05-09SELL-2039.85044.810 44.314USD -886 40.38 Loss of -79 on sale
2025-04-30SELL-2045.61045.810 45.790USD -916 40.13 Loss of -113 on sale
2025-04-24SELL-4040.99041.440 41.395USD -1,656 40.07 Loss of -53 on sale
2025-04-17SELL-2037.63037.850 37.828USD -757 40.16 Profit of 47 on sale
2025-04-15SELL-6038.08039.130 39.025USD -2,342 40.22 Profit of 71 on sale
2025-04-14SELL-6037.60037.840 37.816USD -2,269 40.24 Profit of 146 on sale
2025-04-09SELL-8037.36038.120 38.044USD -3,044 40.39 Profit of 188 on sale
2025-04-07SELL-14035.97038.820 38.535USD -5,395 40.51 Profit of 277 on sale
2025-04-04SELL-20036.73039.990 39.664USD -7,933 40.56 Profit of 179 on sale
2025-03-31BUY2040.48041.120 41.056USD 821 40.56
2025-03-19SELL-4044.78044.910 44.897USD -1,796 40.16 Loss of -189 on sale
2025-03-14SELL-12044.15045.584 45.441USD -5,453 40.00 Loss of -653 on sale
2025-03-13SELL-4044.86045.950 45.841USD -1,834 39.93 Loss of -236 on sale
2025-03-12SELL-68045.85047.110 46.984USD -31,949 39.84 Loss of -4,855 on sale
2025-03-07SELL-4042.12043.940 43.758USD -1,750 39.72 Loss of -161 on sale
2025-03-06SELL-6043.67044.940 44.813USD -2,689 39.66 Loss of -309 on sale
2025-03-03SELL-2045.54048.780 48.456USD -969 39.41 Loss of -181 on sale
2025-02-28SELL-12049.12049.250 49.237USD -5,908 39.25 Loss of -1,198 on sale
2025-02-26SELL-2047.59048.970 48.832USD -977 38.97 Loss of -197 on sale
2025-02-25SELL-6047.47049.660 49.441USD -2,966 38.83 Loss of -637 on sale
2025-02-18BUY10049.44051.390 51.195USD 5,119 37.51
2025-02-13BUY2049.23049.920 49.851USD 997 36.75
2025-02-12BUY2049.44050.700 50.574USD 1,011 36.49
2025-02-11BUY6049.95051.133 51.015USD 3,061 36.21
2025-02-06BUY18054.95057.780 57.497USD 10,349 35.06
2025-01-28BUY2051.47057.480 56.879USD 1,138 31.45
2024-12-30BUY10027.96028.050 28.041USD 2,804 31.37
2024-12-06BUY8031.11031.340 31.317USD 2,505 31.41
2024-12-05BUY2029.70031.060 30.924USD 618 31.47
2024-12-04BUY10030.92031.400 31.352USD 3,135 31.49
2024-11-29BUY10032.10032.740 32.676USD 3,268 31.47
2024-11-27BUY8032.17032.400 32.377USD 2,590 31.41
2024-11-26BUY2031.16032.030 31.943USD 639 31.42
2024-11-21BUY10031.20031.270 31.263USD 3,126 31.34
2024-11-20BUY6030.63531.600 31.504USD 1,890 31.38
2024-11-18BUY24029.56029.850 29.821USD 7,157 31.52
2024-11-12BUY16032.38034.540 34.324USD 5,492 31.46
2024-11-08BUY10034.45034.730 34.702USD 3,470 31.25
2024-11-07BUY30034.87035.875 35.774USD 10,732 30.97
2024-11-06BUY4035.28035.705 35.663USD 1,427 30.61
2024-10-31BUY2030.83031.433 31.373USD 627 29.92
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AKRO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19320,5540439,67772.9%
2025-09-18580,3188,0001,504,42038.6%
2025-09-17204,88220453,80345.1%
2025-09-16206,79620330,74562.5%
2025-09-15220,05926481,70145.7%
2025-09-12353,7940539,61965.6%
2025-09-11255,45091523,79248.8%
2025-09-10448,3407,548553,34681.0%
2025-09-09151,46214,540268,13156.5%
2025-09-08190,27026,862376,99350.5%
2025-09-05117,6830243,94448.2%
2025-09-04194,34829609,13831.9%
2025-09-03127,8543245,66252.0%
2025-09-02116,9863,904277,82742.1%
2025-08-2985,1730146,20958.3%
2025-08-28122,035238187,63865.0%
2025-08-27153,819113232,96766.0%
2025-08-2692,3044,102207,51944.5%
2025-08-2596,7060144,62366.9%
2025-08-22146,1800328,68144.5%
2025-08-2199,543200166,23359.9%
2025-08-20186,4440265,08670.3%
2025-08-19135,6200193,66870.0%
2025-08-18108,3950171,50763.2%
2025-08-15554,6635878,28963.2%
2025-08-14325,70313,249531,75361.3%
2025-08-13127,0860277,10845.9%
2025-08-12187,43230,605288,84464.9%
2025-08-11293,88313,502490,12360.0%
2025-08-08199,0640355,71956.0%
2025-08-07275,5290721,33938.2%
2025-08-06963,4382111,390,49269.3%
2025-08-05318,6384,289433,70373.5%
2025-08-04238,39792375,44263.5%
2025-08-01223,655714301,11874.3%
2025-07-31224,46697335,69166.9%
2025-07-30131,3290227,51257.7%
2025-07-2999,36849195,57550.8%
2025-07-28169,5887309,20654.8%
2025-07-2592,23160188,78448.9%
2025-07-2479,79165200,04439.9%
2025-07-23133,90177303,68744.1%
2025-07-2282,61650289,83328.5%
2025-07-2189,737216210,90142.5%
2025-07-1895,387211239,96839.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.